DR. DREW WEISSMAN, M.D.
Osteopathic Medicine at Woodland Ave, Philadelphia, PA
License number
Pennsylvania MD061254L
Category
Osteopathic Medicine
Type
Allergy & Immunology
Address
Address
2
3900 Woodland Ave, Philadelphia, PA 19104
218 Lloyd Ln, Penn Wynne, PA 19096
218 Lloyd Ln, Penn Wynne, PA 19096
Phone
(215) 823-5800
(610) 645-6501
(610) 645-6501
Personal information
See more information about DREW WEISSMAN at radaris.comName
Address
Phone
218 Lloyd Ln, Wynnewood, PA 19096
218 Lloyd Ln, Ardmore, PA 19003
218 Lloyd Ln, Wynnewood, PA 19096
3600 Hamilton Walk, Philadelphia, PA 19104
Organization information
See more information about DREW WEISSMAN at bizstanding.comDrew Weissman
3400 Spruce St, Philadelphia, PA 19104
Industry:
Medical Doctor's Office, Nonclassifiable Establishments
Medical Doctor:
Gary Eric Weissman (Medical Doctor)
Drew Weissman MD
3900 Woodland Ave, Philadelphia, PA 19104
Industry:
Internist
Phone:
(215) 823-5800 (Phone)
Drew Weissman
Professional information
See more information about DREW WEISSMAN at trustoria.com
Dr. Drew Weissman, Philadelphia PA - MD (Doctor of Medicine)
Dr. Drew Weissman, Philadelphia PA - MD (Doctor of Medicine)
Specialties:
Internal Medicine, Allergy & Immunology
Address:
536 Johnson Pavilion, Philadelphia 19104
3900 Woodland Ave, Philadelphia 19104
(215) 614-0291 (Phone)
3900 Woodland Ave, Philadelphia 19104
(215) 614-0291 (Phone)
Certifications:
Allergy & Immunology, 1993, Internal Medicine, 1990
Awards:
Healthgrades Honor Roll
Languages:
English
Education:
Medical School
Boston University School of Medicine
Graduated: 1987
Beth Israel Deaconess Medical Center
Niaid/Nih
Boston University School of Medicine
Graduated: 1987
Beth Israel Deaconess Medical Center
Niaid/Nih
Drew Weissman, Philadelphia PA
Drew Weissman, Philadelphia PA
Specialties:
Allergy & Immunology, Allergy, Allergy & Immunology
Work:
Philadelphia Veterans Affairs Medical Center
3900 Woodland Ave, Philadelphia, PA 19104
3900 Woodland Ave, Philadelphia, PA 19104
Education:
Boston University(1987)
Rna Containing Modified Nucleosides And Methods Of Use Thereof
Rna Containing Modified Nucleosides And Methods Of Use Thereof
US Patent:
2013026, Oct 3, 2013
Filed:
Mar 15, 2013
Appl. No.:
13/839155
Inventors:
Drew Weissman - Wynnewood PA, US
Assignee:
The Trustees Of the University of Pennsylvania - Philadelphia PA
International Classification:
C07H 21/02
US Classification:
514 44 R, 435 691, 435 61, 435 694, 435189, 435207, 435 6952, 435192, 435 792, 435 611
Abstract:
This invention provides RNA, oligoribonucleotide, and polyribonucleotide molecules comprising pseudouridine or a modified nucleoside, gene therapy vectors comprising same, methods of synthesizing same, and methods for gene replacement, gene therapy, gene transcription silencing, and the delivery of therapeutic proteins to tissue in vivo, comprising the molecules. The present invention also provides methods of reducing the immunogenicity of RNA, oligoribonucleotide, and polyribonucleotide molecules.
Rna Containing Modified Nucleosides And Methods Of Use Thereof
Rna Containing Modified Nucleosides And Methods Of Use Thereof
US Patent:
2013019, Aug 1, 2013
Filed:
Mar 15, 2013
Appl. No.:
13/839023
Inventors:
The Trustees Of The University Of Pennsylvania - Philadelphia PA, US
Drew Weissman - Wynnewood PA, US
Drew Weissman - Wynnewood PA, US
Assignee:
The Trustees Of The University Of Pennsylvania - Philadelphia PA
International Classification:
C07H 21/02
US Classification:
514 44 R, 435 691, 435 694, 435 6952, 435 6951
Abstract:
This invention provides RNA, oligoribonucleotide, and polyribonucleotide molecules comprising pseudouridine or a modified nucleoside, gene therapy vectors comprising same, methods of synthesizing same, and methods for gene replacement, gene therapy, gene transcription silencing, and the delivery of therapeutic proteins to tissue in vivo, comprising the molecules. The present invention also provides methods of reducing the immunogenicity of RNA, oligoribonucleotide, and polyribonucleotide molecules.
Rna Containing Modified Nucleosides And Methods Of Use Thereof
Rna Containing Modified Nucleosides And Methods Of Use Thereof
US Patent:
2013011, May 2, 2013
Filed:
Aug 14, 2012
Appl. No.:
13/585517
Inventors:
Katalin Kariko - Rydal PA, US
Drew Weissman - Wynnewood PA, US
Drew Weissman - Wynnewood PA, US
International Classification:
C07H 21/02
US Classification:
800 18, 435369, 435354, 536 231, 536 232, 536 235, 424400, 514 44 R
Abstract:
This invention provides RNA, oligoribonucleotide, and polyribonucleotide molecules comprising pseudouridine or a modified nucleoside, gene therapy vectors comprising same, methods of synthesizing same, and methods for gene replacement, gene therapy, gene transcription silencing, and the delivery of therapeutic proteins to tissue in vivo, comprising the molecules. The present invention also provides methods of reducing the immunogenicity of RNA, oligoribonucleotide, and polyribonucleotide molecules.
Rna Preparations Comprising Purified Modified Rna For Reprogramming Cells
Rna Preparations Comprising Purified Modified Rna For Reprogramming Cells
US Patent:
2011014, Jun 16, 2011
Filed:
Dec 7, 2010
Appl. No.:
12/962468
Inventors:
Katalin Kariko - Rydal PA, US
Drew Weissman - Wynnewood PA, US
Gary Dahl - Madison WI, US
Anthony Person - Madison WI, US
Judith Meis - Fitchburg WI, US
Jerome Jendrisak - Madison WI, US
Drew Weissman - Wynnewood PA, US
Gary Dahl - Madison WI, US
Anthony Person - Madison WI, US
Judith Meis - Fitchburg WI, US
Jerome Jendrisak - Madison WI, US
International Classification:
C12N 5/071, C12P 21/00
US Classification:
435 703, 435377, 435366
Abstract:
The present invention provides compositions and methods for reprogramming somatic cells using purified RNA preparations comprising single-strand mRNA encoding an iPS cell induction factor. The purified RNA preparations are preferably substantially free of RNA contaminant molecules that: i) would activate an immune response in the somatic cells, ii) would decrease expression of the single-stranded mRNA in the somatic cells, and/or iii) active RNA sensors in the somatic cells. In certain embodiments, the purified RNA preparations are substantially free of partial mRNAs, double-stranded RNAs, un-capped RNA molecules, and/or single-stranded run-on mRNAs.
Prevention Of Hiv Infection
Prevention Of Hiv Infection
US Patent:
2011008, Apr 14, 2011
Filed:
Jun 8, 2007
Appl. No.:
12/303985
Inventors:
Drew Weissman - Wynnewood PA, US
Stoddard Earl - Philadelphia PA, US
Stoddard Earl - Philadelphia PA, US
Assignee:
THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA - Philidelphia PA
International Classification:
A61K 39/395, A61K 38/10, C12N 5/071, C07K 16/18, C07K 7/08, G01N 33/566, A61P 31/12, A61P 31/18
US Classification:
4241351, 4241331, 514 38, 514 37, 4241721, 4241521, 435375, 5303891, 530326, 5303873, 5303882, 436501
Abstract:
This invention relates to methods compositions and devices for inhibiting infection of a subject's host cell by HIV. Specifically, the invention relates to methods and compositions capable of inhibiting the binding and subsequent infection by HIV of a host cell through the inhibition of the interaction between gp-340 expressed on the cell surface and V3 loop on the HIV envelope and devices comprising these compositions.
Rna Containing Modified Nucleosides And Methods Of Use Thereof
Rna Containing Modified Nucleosides And Methods Of Use Thereof
US Patent:
8278036, Oct 2, 2012
Filed:
Aug 21, 2006
Appl. No.:
11/990646
Inventors:
Katalin Kariko - Rydal PA, US
Drew Weissman - Wynnewood PA, US
Drew Weissman - Wynnewood PA, US
Assignee:
The Trustees of the University of Pennsylvania - Philadelphia PA
International Classification:
C12Q 1/68
US Classification:
435 6, 435325, 435375
Abstract:
This invention provides RNA, oligoribonucleotide, and polyribonucleotide molecules comprising pseudouridine or a modified nucleoside, gene therapy vectors comprising same, methods of synthesizing same, and methods for gene replacement, gene therapy, gene transcription silencing, and the delivery of therapeutic proteins to tissue in vivo, comprising the molecules. The present invention also provides methods of reducing the immunogenicity of RNA, oligoribonucleotide, and polyribonucleotide molecules.